{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:31:20Z","timestamp":1789651880333,"version":"4.0.0"},"reference-count":29,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Israel Institute for Biological Research","award":["SB\/5112-211"],"award-info":[{"award-number":["SB\/5112-211"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Yersinia pestis is a Gram-negative pathogen that causes plague, a devastating disease that kills millions worldwide. Although plague is efficiently treatable by recommended antibiotics, the time of antibiotic therapy initiation is critical, as high mortality rates have been observed if treatment is delayed for longer than 24 h after symptom onset. To overcome the emergence of antibiotic resistant strains, we attempted a systematic screening of Food and Drug Administration (FDA)-approved drugs to identify alternative compounds which may possess antibacterial activity against Y. pestis. Here, we describe a drug-repurposing approach, which led to the identification of two antibiotic-like activities of the anticancer drugs bleomycin sulfate and streptozocin that have the potential for designing novel antiplague therapy approaches. The inhibitory characteristics of these two drugs were further addressed as well as their efficiency in affecting the growth of Y. pestis strains resistant to doxycycline and ciprofloxacin, antibiotics recommended for plague treatment.<\/jats:p>","DOI":"10.3390\/antibiotics10010040","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T19:54:46Z","timestamp":1609703686000},"page":"40","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Screening of an FDA-Approved Library for Novel Drugs against Y. pestis"],"prefix":"10.3390","volume":"10","author":[{"given":"David","family":"Gur","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, 24 Reuven Lerer, Ness Ziona 74010001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodor","family":"Chitlaru","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, 24 Reuven Lerer, Ness Ziona 74010001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5685-293X","authenticated-orcid":false,"given":"Emanuelle","family":"Mamroud","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, 24 Reuven Lerer, Ness Ziona 74010001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayelet","family":"Zauberman","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, 24 Reuven Lerer, Ness Ziona 74010001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/CMR.10.1.35","article-title":"Yersinia pestis--etiologic agent of plague","volume":"10","author":"Perry","year":"1997","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","unstructured":"(2020, December 01). Plague, Available online: https:\/\/www.cdc.gov\/plague."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1473-3099(18)30730-8","article-title":"Epidemiological characteristics of an urban plague epidemic in Madagascar, August-November, 2017: An outbreak report","volume":"19","author":"Randremanana","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1086\/428617","article-title":"Risk of person-to-person transmission of pneumonic plague","volume":"40","author":"Kool","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1128\/AAC.00306-06","article-title":"Resistance of Yersinia pestis to antimicrobial agents","volume":"50","author":"Galimand","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijantimicag.2017.09.015","article-title":"Plasmid-mediated doxycycline resistance in a Yersinia pestis strain isolated from a rat","volume":"51","author":"Cabanel","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.coi.2013.08.004","article-title":"Drug repurposing: A better approach for infectious disease drug discovery?","volume":"25","author":"Law","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fmicb.2019.00041","article-title":"Drug Repurposing for the Treatment of Bacterial and Fungal Infections","volume":"10","author":"Smani","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_9","unstructured":"CLSI (2015). M45 Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria, Clinical and Laboratories Standard Institute."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1128\/AEM.65.9.3862-3866.1999","article-title":"Generalized transduction of small Yersinia enterocolitica plasmids","volume":"65","author":"Hertwig","year":"1999","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0723-2020(00)80020-X","article-title":"Comparative study of temperate bacteriophages isolated from Yersinia","volume":"23","author":"Popp","year":"2000","journal-title":"Syst. Appl. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/jphp.12432","article-title":"A novel application of radiomimetic compounds as antibiotic drugs","volume":"67","author":"Andros","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_13","first-page":"230","article-title":"Streptozotocin, a new antibacterial antibiotic","volume":"7","author":"Vavra","year":"1959","journal-title":"Antibiot. Annu."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Murray, V., Chen, J.K., and Chung, L.H. (2018). The Interaction of the Metallo-Glycopeptide Anti-Tumour Drug Bleomycin with DNA. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051372"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1093\/nar\/4.10.3573","article-title":"DNA double-strand breaks and alkali-labile bonds produced by bleomycin","volume":"4","author":"Povirk","year":"1977","journal-title":"Nucleic Acids Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1383-5742(02)00044-3","article-title":"Genotoxicity of streptozotocin","volume":"512","author":"Bolzan","year":"2002","journal-title":"Mutat. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fmicb.2019.00754","article-title":"A Rapid Antimicrobial Susceptibility Test for Determining Yersinia pestis Susceptibility to Doxycycline by RT-PCR Quantification of RNA Markers","volume":"10","author":"Shifman","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_19","first-page":"763","article-title":"A Rapid Molecular Test for Determining Yersinia pestis Susceptibility to Ciprofloxacin by the Quantification of Differentially Expressed Marker Genes","volume":"7","author":"Shifman","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2174\/1568026616666160930131737","article-title":"Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections","volume":"17","author":"Soo","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1517\/21678707.2015.1039510","article-title":"Miltefosine, an FDA-approved drug for the \u2018orphan disease\u2019, leishmaniasis","volume":"3","author":"Berman","year":"2015","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_22","unstructured":"(2020, December 01). A phase 2 IV gallium study for patients with cyctic fibrosis, Available online: http\/\/clinicaltrials.gov\/ct2\/show\/NCT02354859."},{"key":"ref_23","unstructured":"(2020, December 01). Antibacterial agent in clinical development. Available online: https:\/\/www.who.int\/medicines\/areas\/rational_use\/antibacterial_agents_clinical_development\/en\/."},{"key":"ref_24","first-page":"e1403","article-title":"A Review on Antibiotic Resistance: Alarm Bells are Ringing","volume":"9","author":"Zaman","year":"2017","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rawson, T.M., Moore, L.S.P., Zhu, N., Ranganathan, N., Skolimowska, K., Gilchrist, M., Satta, G., Cooke, G., and Holmes, A. (2020). Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciaa530"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhang, J., Yakovlieva, L., de Haan, B.J., de Vos, P., Minnaard, A.J., Witte, M.D., and Walvoort, M.T.C. (2020). Selective Modification of Streptozotocin at the C3 Position to Improve Its Bioactivity as Antibiotic and Reduce Its Cytotoxicity towards Insulin-Producing beta Cells. Antibiotics, 9.","DOI":"10.20944\/preprints202003.0244.v1"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1038\/emi.2016.123","article-title":"Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria","volume":"5","author":"Sun","year":"2016","journal-title":"Emerg. Microbes Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1128\/IAI.00097-06","article-title":"Interaction of Yersinia pestis with macrophages: Limitations in YopJ-dependent apoptosis","volume":"74","author":"Zauberman","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tidhar, A., Levy, Y., Zauberman, A., Vagima, Y., Gur, D., Aftalion, M., Israeli, O., Chitlaru, T., Ariel, N., and Flashner, Y. (2019). Disruption of the NlpD lipoprotein of the plague pathogen Yersinia pestis affects iron acquisition and the activity of the twin-arginine translocation system. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007449"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/1\/40\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:06:35Z","timestamp":1760159195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/1\/40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["antibiotics10010040"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10010040","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]}}}